Search 

MediBase Group is an ITALIAN industrial company that has been operating since 1995 in the field of phytotherapy and medical dietetics; was one of the first companies to deal with Nutraceuticals through the preparation of products addressed exclusively to the health care professionals and distributed through the pharmacies, nursing homes and hospitals.
Titration and standardization are the most important quality criteria in the preparation of MediBase products.
The formulation of our preparations, the choice of active ingredients and their titration are based on accurate studies and analyzes of clinical works, published in the most prestigious international scientific journals, by our R&D.

Global leading Medtech company

MedWorld Advisors is an international M&A Services Firm. We represent medical technology companies from the US, EU and Israel that want to enter the China market. We facilitate licensing, commercialization and acquisition deals between our clients and larger companies / investors in China. We are based in Boston in the U.S. We also have an operation in Hong Kong to help facilitate deals, as helpful.

Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. The technology discerns key biomarkers to stratify patients more precisely, signal treatment resistance as it begins, and predict relapse for better patient outcomes. Application areas include blood cancers, solid tumors, and genome editing validation.

Researchers at Memorial Sloan Kettering Cancer Center (MSK), MD Anderson Cancer Center (MDACC), and the University of California at San Francisco (UCSF) have leveraged the Tapestri Platform to support their research for characterizing clonal dynamics in a variety of cancers, identifying minimal residual disease (MRD), and monitoring treatment response and therapy resistance. The company’s award-winning technology is also leveraged by LabCorp and Agios to enable more efficient clinical trials.

Nenupharma was born out of a shared passion to contribute to the development of innovative pharmaceuticals in different disease areas.

Nenupharma uses the best of skills that have been developed through an extensive career in pharmaceutical industry, regulatory affairs, market access, medical practice and life science.

Nenupharma has been working with high level experts on different levels and enjoys reliable, professional and ethical reputation among its network as well as its customers.

For more information, visit our website at:
www.nenupharma.com

NLC European Healthcare Venture Builder 是一家总部位于荷兰的欧洲医疗科技企业创设公司,在法国、德国和奥地利设有分支机构。NLC 每年筛选超过 3,000 项欧洲最新的医疗专利技术和发明,从中挑选出最具潜力的创新技术并创建公司。NLC 旗下已拥有数十家医疗科技企业,横跨治疗设备、诊断、影像、细胞疗法、AI 人工智能、神经网络、智慧医疗等国内热门医疗领域和紧缺方向,且在技术成熟度、治疗领域和技术类型上拥有充分的多样性,进一步分散了投资风险。

Nuance Biotech (Shanghai) Co. Ltd was founded in 2014.
Leading China based biotech company focussed on commercial, regulatory and development stage assets.
Nuance is directed by a world class board of directors and managed by an experienced China based management team with a strong track record. Backed a leading global tier 1 investor with more than USD 1 billion under management in China – Matrix Partners. The company strategy and approach allows for a highly scalable commercial and drug development model i.e. ability to run multiple initiatives.

Olympus was founded in 1919 and launched our first gastro-camera in the 1950s. Since then, Olympus developed into a MedTech leader, designing and delivering innovative solutions for medical and surgical procedures, especially in the field of endoscopy.

Opera CRO is an international contract research organization (CRO) with offices in Italy (Genoa), in Switzerland (Geneva) and in Romania (Timisoara) that has been managing clinical trials since 1995. In particular, we performed several clinical studies with medical devices, medical drugs and food supplements in many different therapeutic areas.

We offer the possibility of conducting clinical trials in different countries in Eastern Europe, with reduced costs and faster times, or in other European and non-European countries (Italy, France, Switzerland, Germany etc..). Additionally, we offer specific support for the compliance of medical device registrations of the CE marking to the new European regulation. Recently, Opera CRO was acquired by the Tigermed group, the largest CRO in Asia with over 5000 employees and 100 offices. This partnership offers the opportunity to perform clinical trials in China and in the rest of Asia and access that vast market.
The list of our current studies can be found on ClinicalTrial.gov (specifying Opera CRO for Europe, Tigermed for Asia); further information is available on our website: www.operacro.com.